Floatz logo

GENETICALLY-MODIFIED ONCOLYTIC TYPE 5 ADENOVIRUS WHICH SELECTIVELY REPLICATES IN TUMOR CELLS CONTAINING DYSFUNCTIONAL P53 GENE (H101)

Hepatocellular Carcinoma

Fudan Universitygene_therapyPhase 3Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
65/ 100

Competitive context

520 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

GENETICALLY-MODIFIED ONCOLYTIC TYPE 5 ADENOVIRUS WHICH SELECTIVELY REPLICATES IN TUMOR CELLS CONTAINING DYSFUNCTIONAL P53 GENE (H101) is also rated in:

Malignant HydrothoraxDormant
B
Indicative ·
60 / 100
View asset →
metastasis from malignant tumor of colonDormant
CCC
Indicative ·
53 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →